MediPharm Labs Corp.
LABS.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -17.63% | -14.40% | -7.76% | 15.70% | 12.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -17.63% | -14.40% | -7.76% | 15.70% | 12.83% |
| Cost of Revenue | -32.06% | -5.48% | -21.08% | 33.94% | 16.37% |
| Gross Profit | 12.28% | -26.28% | 36.09% | -21.60% | 6.14% |
| SG&A Expenses | -44.18% | -14.38% | 1.22% | -18.33% | 27.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -37.41% | 98.79% | 117.81% | -17.20% | -334.02% |
| Total Operating Expenses | -38.03% | -8.62% | -12.40% | 8.93% | 20.64% |
| Operating Income | 102.12% | -133.67% | 44.39% | 16.60% | -54.15% |
| Income Before Tax | 100.10% | -131.18% | -14.49% | 23.53% | -44.34% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 100.10% | -131.18% | -14.49% | 23.53% | -44.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 100.10% | -131.18% | -14.49% | 23.53% | -44.34% |
| EBIT | 102.12% | -133.67% | 44.39% | 16.60% | -54.15% |
| EBITDA | 113.36% | -4,457.14% | 53.42% | 15.40% | -96.57% |
| EPS Basic | 100.00% | -150.00% | -10.00% | 24.49% | -40.43% |
| Normalized Basic EPS | 102.44% | -125.00% | 44.44% | 23.33% | -51.85% |
| EPS Diluted | 100.00% | -150.00% | -10.00% | 24.49% | -40.43% |
| Normalized Diluted EPS | 102.44% | -125.00% | 44.44% | 23.33% | -51.85% |
| Average Basic Shares Outstanding | 2.45% | 2.35% | 2.40% | 2.36% | 2.61% |
| Average Diluted Shares Outstanding | 2.45% | 2.35% | 2.40% | 2.36% | 2.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |